Summary

The South & Central America infectious disease therapeutics market was valued at US$ 6,252.96 million in 2022 and is expected to reach US$ 8,167.05 million by 2030; it is estimated to register a CAGR of 3.4% from 2022 to 2030.

Growing Opportunities in Developing Nations Fuels South & Central America Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in Brazil are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

South & Central America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in South & Central America is sub segmented into Brazil, Argentina, and the Rest of South & Central America. The infectious disease therapeutics market in South & Central America is expected to grow due to increased prevalence of infectious diseases, surge in research activities, and rising healthcare expenditure by the regional countries. Brazil has made huge progress in the healthcare sector owing to expanding healthcare expenditure. According to the International Trade Administration, Brazil spends ~9.1% of its GDP on healthcare and is the major healthcare market in Latin America. The infectious disease therapeutics market in Brazil is estimated to boom owing to the increasing prevalence of infectious diseases.

Infectious diseases are still significant causes of death in Brazil. A survey revealed that a high burden of infectious disease was observed among men and children under 5 years of age, mainly due to HIV/AIDS. According to the data provided by the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, around 990,000 people were living with HIV and AIDS in Brazil. Thus, owing to the abovementioned factors, the infectious disease therapeutics market in Brazil is anticipated to grow during the forecast period.

South & Central America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Infectious Disease Therapeutics Market Segmentation

The South & Central America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the South & Central America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the South & Central America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the South & Central America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the South & Central America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the South & Central America infectious disease therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the South & Central America infectious disease therapeutics market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - South & Central America Market Analysis
5.1 South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. South & Central America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Infectious Disease Therapeutics Market - Country Analysis
10.1 South & Central America Infectious Disease Therapeutics Market
10.1.1 South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Brazil: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.2.2 Brazil: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.2.3 Brazil: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.2.4 Brazil: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.3 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.4 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Argentina: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.4.2 Argentina: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.4.3 Argentina: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.4.4 Argentina: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.5 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.6 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.6.2 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.6.3 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.6.4 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners